AAV2 Vector Transduction of Primary Cilia for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kidney diseases such as polycystic kidney disease (PKD) and macular degeneration, particularly autosomal dominant PKD and Malattia Leventinese, lack effective solutions, with PKD leading to renal failure and macular degeneration causing significant visual impairment, and existing gene therapies face challenges in stable and efficient transduction of target cells.
Innovation Solution
Employing recombinant serotype 2 adeno-associated virus (AAV) vectors for transducing primary cilia in kidney and retinal cells, delivering transgenes to correct genetic defects in PKD and EFEMP1 mutations, thereby addressing cellular dysfunction and pathology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy methods are used to treat kidney diseases, then genetic defects can be targeted, but stable and efficient transduction of target cells is not achieved
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver therapeutic genes to target cells. The AAV vector acts as a mediator between the genetic material and the target cells, enabling efficient and stable transduction by facilitating viral entry and genomic integration without causing disease
Solution Approach 2:
The patent employs different serotypes of AAV vectors (AAV2, AAV5, AAV8, AAV9) with varying biological properties to optimize transduction efficiency for different target cells. By changing the viral vector parameters (serotype selection), the patent achieves both stable and efficient transduction in renal and retinal cells
2Reliability
If AAV vectors are used for gene delivery, then stable integration into host genome is achieved, but transduction of cells with primary cilia is insufficient
Solution Approach 1:
The patent demonstrates that AAV vectors have universal applicability across different cell types, particularly cells with primary cilia such as renal tubular epithelial cells and retinal pigment epithelial cells. The same AAV vector system can target multiple tissue types and deliver different therapeutic genes, achieving both stable integration and broad transduction coverage
3Ease of operation
If current treatments are used for PKD and macular degeneration, then supportive care is provided, but disease progression is not halted
Solution Approach 1:
The patent applies gene therapy before disease progression becomes irreversible by delivering corrective genes early in the disease course. For PKD, the therapeutic gene is delivered to prevent cyst formation; for macular degeneration, the EFEMP1 gene is delivered before significant retinal damage occurs, halting progression before end-stage disease develops
Data Source
AI summary
This invention provides methods for transducing a ciliated cell with a recombinant serotype 2 adeno-associated virus (AAV) vector. Additionally, the invention provides methods of treating diseases associated with a mutated gene by transducing a ciliated cell with a recombinant serotype 2 AAV vector containing a corrective transgene.